Intellia is a pioneer in the development of CRISPR/Cas9 genome editing and is rapidly moving experimental therapies towards the clinic.
Our company’s unique strengths include our modular lipid nanoparticle delivery system and our determined focus on product development.
Each one of us together for patients
We believe our modular approach to selecting our in vivo and ex vivo programs positions us to build a full-spectrum genome editing company, with a pipeline across a range of indications. This approach enables us to generate a wealth of data that opens the potential therapeutic applications of the CRISPR/Cas9 technology across a broad range of diseases.
Intellia Genomics Director, Jessica Seitzer, will present new data on the #CRISPR/Cas9-mediated gene knockout of KLKB1 to treat #hereditaryangioedema at @AAAAI_org’s annual meeting virtually tomorrow from 5:10-6:25 p.m. CST. Be sure to tune in! https://t.co/o0Szu7iiWu
$NTLA announced today its fourth quarter and full-year 2020 financial results. Full details here: https://t.co/s0Jksqdad0 #CRISPR #genomeediting https://t.co/IyT7qT2EZy